Oki, Eiji; Makiyama, Akitaka; Miyamoto, Yuji; Kotaka, Masahiko; Kawanaka, Hirofumi; Miwa, Keisuke; Kabashima, Akira; Noguchi, Tomohiro; Yuge, Kotaro; Kashiwada, Tomomi; Ando, Koji; Shimokawa, Mototsugu; Saeki, Hiroshi; Akagi, Yoshito; Baba, Hideo; Maehara, Yoshihiko; Mori, Masaki published an article in 2021, the title of the article was Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:
A previous Phase I/II study demonstrated that TAS-102 (trifluridine/tipiracil) plus bevacizumab has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing efficacy and safety of FTD/TPI plus Bev in elderly patients with previously untreated metastatic colorectal cancer. Treatment consisted of FTD/TPI plus Bev given every 4 wk. Primary endpoint was progression-free survival, assuming null hypothesis of PFS of 5 mo. Secondary endpoints were the overall survival, overall response rate, and adverse events. Between 5 Jan. 2017 and 13 March 2018, 39 patients were enrolled from 18 institutions. Median patient age was 76.0 years (range, 70-88); the ECOG-PS was 0 in 24 patients and 1 in 15 patients. Median PFS was 9.4 mo as a primary endpoint, and the median OS was 22.4 mo. The ORR was 40.5% and the disease control rate was 86.5%. Grade 3-4 AEs included neutropenia, leukopenia, anorexia, febrile neutropenia, and fatigue. FTD/TPI plus Bev is effective and well-tolerated regimen for elderly patients with previously untreated metastatic colorectal cancer. Capecitabine/bevacizumab can be selected as subsequent maintenance therapy without irinotecan and oxaliplatin because FTD/TPI has no cross-resistance with 5-fluorouracil. Clin. trial registration, UMIN clin. trials registry (UMIN000025241). The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione
The Article related to metastatic colorectal cancer trifluridine tipiracil bevacizumab phase ii, trifluridine, bevacizumab, colorectal cancer, elderly, thymidine phosphorylase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia